Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

THERMO FISHER SCIENTIFIC

(TMO)
  Report
Delayed Nyse  -  04:00 2022-12-06 pm EST
550.53 USD   -1.20%
08:16aRBC Initiates Thermo Fisher Scientific at Outperform With $660 Price Target, Cites 'Advantageous Position'
MT
12/06Thermo Fisher Scientific Raises Greenhouse Gas Emissions Reduction Target on Path to Net-zero Emissions
BU
11/29Transcript : Thermo Fisher Scientific Inc. Presents at 5th Annual Evercore ISI HealthCONx Conference 2022, Nov-29-2022 10:30 AM
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Thermo Fisher Scientific Announces FDA Approval of Oncomine Dx Target Test as the First NGS-Based Companion Diagnostic to Aid in Therapy Selection for Patients with RET Mutations/Fusions in Thyroid Cancers

09/27/2022 | 04:30pm EST

Thermo Fisher Scientific Inc. announced that the U.S. Food and Drug Administration (FDA) has granted approval to the company's Oncomine Dx Target Test as a companion diagnostic (CDx) to aid in selection of patients with RET-fusion positive locally advanced or metastatic non-small cell lung cancer (NSCLC), RET-fusion positive advanced or metastatic thyroid cancer and RET-mutation positive advanced or metastatic medullary thyroid cancer (MTC) who may be eligible for treatment with Lilly's Retevmo (selpercatinib). This marks the Oncomine Dx Target Test's first approval as a CDx for a therapy targeting RET-positive thyroid cancer and second approval associated with RET-positive NSCLC. Initially approved in 2020, Retevmo is a selective RET kinase inhibitor and was the first therapy approved for patients with advanced RET-driven lung and thyroid cancers.

RET (rearranged during transfection) alterations are found in approximately 2% of patients with NSCLC, which is the leading cause of adult cancer death in the United Statesi, 60% of patients with MTC and 20% in other thyroid cancers.ii The Oncomine Dx Target test is a next-generation sequencing (NGS)-based test that can detect multiple alterations at once from a small sample size, helping to quickly match patients with the appropriate targeted therapy. It is also approved in Japan as a companion diagnostic for Retevmo in the same indications. The test is the only globally distributable NGS CDx solution that has received regulatory approval in 17 countries for 15 targeted therapies, covering more than 550 million lives globally.


ę S&P Capital IQ 2022
All news about THERMO FISHER SCIENTIFIC
08:16aRBC Initiates Thermo Fisher Scientific at Outperform With $660 Price Target, Cites 'Adv..
MT
12/06Thermo Fisher Scientific Raises Greenhouse Gas Emissions Reduction Target on Path to Ne..
BU
11/29Transcript : Thermo Fisher Scientific Inc. Presents at 5th Annual Evercore IS..
CI
11/29Barclays Cuts Price Target on Thermo Fisher to $570 From $575, Maintains Overweight Rat..
MT
11/21Thermo Fisher Scientific Issues 1.25 Billion Euros of 2026, 2034 Notes
MT
11/21Thermo Fisher Scientific Inc. : Entry into a Material Definitive Agreement, Other Events, ..
AQ
11/21Thermo Fisher Scientific to Present at Evercore ISI HealthCONx Conference
BU
11/18Insider Sell: Thermo Fisher Scientific
MT
11/16Thermo Fisher Scientific : Introduces Rapid Point-of-Care RT-PCR Flu A/Flu B Test
PU
11/16Thermo Fisher Scientific to Seek Acquisitions
CI
More news
Analyst Recommendations on THERMO FISHER SCIENTIFIC
More recommendations
Financials (USD)
Sales 2022 43 903 M - -
Net income 2022 6 919 M - -
Net Debt 2022 24 827 M - -
P/E ratio 2022 31,4x
Yield 2022 0,21%
Capitalization 217 B 217 B -
EV / Sales 2022 5,51x
EV / Sales 2023 5,38x
Nbr of Employees 130 000
Free-Float 88,9%
Chart THERMO FISHER SCIENTIFIC
Duration : Period :
Thermo Fisher Scientific Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERMO FISHER SCIENTIFIC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 550,53 $
Average target price 617,84 $
Spread / Average Target 12,2%
EPS Revisions
Managers and Directors
Marc N. Casper Chairman, President & Chief Executive Officer
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Alan B. Sachs Chief Medical Officer
Karen E. Nelson Chief Scientific Officer
Sector and Competitors